Den mest almindelige bivirkning, som blev rapporteret med en højere incidens hos patienter, der var i aprepitantbehandling end i standardbehandling hos patienter, der var i behandling med moderat emetogen kemoterapibehandling var træthed (2, 5% mod 1, 6%).
The most common adverse reaction reported at a greater incidence in patients treated with the aprepitant regimen than with standard therapy in patients receiving moderately emetogenic chemotherapy was fatigue (2.5% versus 1.6%).